Induction of immunosuppressive functions and NF-&#954;B by FLIP in monocytes by Fiore, Alessandra et al.
ARTICLE
Induction of immunosuppressive functions
and NF-κB by FLIP in monocytes
Alessandra Fiore1,17, Stefano Ugel1, Francesco De Sanctis1, Sara Sandri1, Giulio Fracasso 1, Rosalinda Trovato1,
Silvia Sartoris1, Samantha Solito2, Susanna Mandruzzato2,3, Fulvia Vascotto4, Keli L. Hippen5,
Giada Mondanelli 6, Ursula Grohmann6, Geny Piro7,8, Carmine Carbone7, Davide Melisi 7, Rita T. Lawlor9,
Aldo Scarpa 9,10, Alessia Lamolinara 11, Manuela Iezzi 11, Matteo Fassan 12, Silvio Bicciato13,
Bruce R. Blazar5, Ugur Sahin4,14,15, Peter J. Murray16 & Vincenzo Bronte1
Immunosuppression is a hallmark of tumor progression, and treatments that inhibit or
deplete monocytic myeloid-derived suppressive cells could promote anti-tumor immunity. c-
FLIP is a central regulator of caspase-8-mediated apoptosis and necroptosis. Here we show
that low-dose cytotoxic chemotherapy agents cause apoptosis linked to c-FLIP down-reg-
ulation selectively in monocytes. Enforced expression of c-FLIP or viral FLIP rescues mono-
cytes from cytotoxicity and concurrently induces potent immunosuppressive activity, in T cell
cultures and in vivo models of tumor progression and immunotherapy. FLIP-transduced
human blood monocytes can suppress graft versus host disease. Neither expression of FLIP in
granulocytes nor expression of other anti-apoptotic genes in monocytes conferred immu-
nosuppression, suggesting that FLIP effects on immunosuppression are specific to monocytic
lineage and distinct from death inhibition. Mechanistically, FLIP controls a broad transcrip-
tional program, partially by NF-κB activation. Therefore, modulation of FLIP in monocytes
offers a means to elicit or block immunosuppressive myeloid cells.
DOI: 10.1038/s41467-018-07654-4 OPEN
1 Department of Medicine, Section of Immunology, University of Verona, Verona 37134, Italy. 2 Department of Surgery, Oncology and Gastroenterology,
Section of Oncology and Immunology, University of Padova, Padova 35124, Italy. 3 Istituto Oncologico Veneto IOV-IRCCS, Padova 35124, Italy. 4 TRON-
Translational Oncology, University Medical Center of Johannes Gutenberg University, Mainz 55131, Germany. 5 Department of Pediatrics, Division of Blood
and Marrow Transplantation, University of Minnesota, Minneapolis 55455 MN, USA. 6Department of Experimental Medicine, University of Perugia, Perugia
06132, Italy. 7 Department of Medicine, Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona 37134, Italy. 8 Department of
Medicine, Laboratory of Oncology and Molecular Therapy, University of Verona, Verona 37134, Italy. 9 ARC-Net Centre for Applied Research on Cancer,
University and Hospital Trust of Verona, Verona 37134, Italy. 10 Department of Pathology and Diagnostics, University of Verona, Verona 37134, Italy.
11 Department of Medicine and Aging Science, Center of Excellence on Aging and Translational Medicine (CeSi-Met), University G. D’Annunzio of Chieti-
Pescara, Chieti 66100, Italy. 12 Department of Medicine-DIMED, University of Padova, Padova 35124, Italy. 13 Department of Life Sciences, Center for
Genome Research, University of Modena and Reggio Emilia, Modena 41100, Italy. 14 University Medical Center of the Johannes Gutenberg University, Mainz
55131, Germany. 15 Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz 55131, Germany. 16Max Planck Institute of Biochemistry,
Martinsried 82152, Germany. 17Present address: Max Planck Institute of Biochemistry, Martinsried 82152, Germany. These authors contributed equally:
Alessandra Fiore, Stefano Ugel. Correspondence and requests for materials should be addressed to S.U. (email: stefano.ugel@univr.it)
or to P.J.M. (email: murray@biochem.mpg.de) or to V.B. (email: vincenzo.bronte@univr.it)
NATURE COMMUNICATIONS |          (2018) 9:5193 | DOI: 10.1038/s41467-018-07654-4 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
The current treatments for cancer patients rely on cytotoxicagents able to destroy malignant cells1 that have acquireddistinctive chronic proliferation by evading from cell death
checkpoints, as well as by self-generating proliferative signals2. At
the same time, chemotherapy can cause systemic immune mod-
ulation at multiple levels3,4. For example, some chemother-
apeutics induce immune depression by favoring myelo- and
lympho-penia5; on the other hand, chemotherapeutic drugs can
exert immune stimulatory actions by favoring the activation of
anti-tumor T cells, both through the induction of immunogenic
tumor cell death3,6 and containment of immunosuppressive
immune cell populations, such as regulatory T cells (Treg) and
myeloid-derived suppressor cells (MDSCs)7,8. Chemotherapy can
thus be used to restore immune responses in tumor-bearing
hosts. Certain pharmacologically active substances can eliminate
monocytic (M)-MDSCs in different preclinical models9 and
carboplatin and paclitaxel normalized myeloid cell numbers in
advanced cervical cancer patients, increasing the response to a
peptide-based vaccine8. Considering the many unwanted side
effects of chemotherapy, however, definition of the intracellular
targets accounting for the exquisite activity of different che-
motherapeutics on M-MDSCs is needed for focused molecular
approaches. For instance, monocyte/macrophage depletion by
trabectedin depends on increased levels of membrane death
receptors (Fas and tumor necrosis factor-related apoptosis
inducing ligand [TRAIL] receptor 2) that facilitate the recruit-
ment of caspase-8 and the activation of the apoptotic cascade10.
However, this biological modulation might not be shared by other
drugs.
The major player in TRAIL-induced apoptosis resistance is
cellular FLICE (FADD-like IL-1β-converting enzyme)-inhi-
bitory protein (c-FLIP)11. The gene encoding c-FLIP (CFLAR)
is conserved in vertebrates and structurally similar to viral
FLICE-inhibitory protein (v-FLIP) that is encoded in the
genome of gamma herpesviruses such as the human herpes-
virus 8, the Kaposi’s sarcoma-associated virus12,13. It is acti-
vated by several stimuli, such as growth factors, tumor
necrosis factor (TNF)-ligands and chemotherapy and it is
transcriptionally regulated, especially by nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB)14. In turn, c-
FLIP regulates important processes maintaining immune
system homeostasis: it protects mature T lymphocytes from
activation-induced cell death15, it controls Treg homeostasis16
and survival from FasL-mediating killing by tumor endothe-
lium17, as well as Fas sensitivity of monocytes and monocyte-
derived cells, such as dendritic cells (DCs) and
macrophages18,19 and their viability in the bone marrow
during normal development20. Recently, c-FLIP expression
was shown to represent a conditio sine qua non for tumor-
induced, M-MDSC generation21.
FLIP expression might buy time for myeloid cells and protect
monocytes and macrophages, allowing them to perform their
functions in a hostile inflammatory environment. This is likely
the case for cancer21 but it also applies to lung macrophages
during post-damage fibrosis22; moreover, FLIP can also limit the
negative consequences of caspase-8 activation by inflammasome
sensors in macrophages23. Thus, FLIP may have acquired other
properties during the evolution, contributing more directly to
dampen the inflammation in a monocyte/macrophage extrinsic
fashion. Here we report a dual role of FLIP in myeloid cells. We
found that drugs able to restrain FLIP expression selectively
eliminate M-MDSCs but not polymorphonuclear (PMN)-MDSCs
restoring T cell responses; more importantly, expression of FLIP
in human normal myeloid precursors and monocytes is sufficient
to confer the immune suppressive properties associated with
MDSCs.
Results
c-FLIP protects M-MDSCs from chemotherapy-induced kill-
ing. We previously reported that low doses of diverse chemother-
apeutic drugs, which are unable to control tumor growth, selectively
affect the numbers of circulating CD11b+Ly6G−Ly6Chigh cells and
enhance the efficacy of adoptive cell therapy (ACT)9. To understand
the molecular basis of this differential susceptibility, we compared 10
conventional anti-cancer drugs to test their ability to modulate
in vitro CD11b+Ly6G−Ly6Chigh cell viability during bone marrow
(BM)-MDSC differentiation24. After testing different doses of each
drug, we defined the highest drug concentration that did not cause
overt toxicity, i.e. ≥ 75% of cells were viable at the end of culture
(Supplementary Fig. 1a, b). Except for fludarabine and carboplatin,
the addition of all the tested chemotherapeutics caused a redis-
tribution within the myeloid subsets (Fig. 1a and Supplementary
Fig. 1c), characterized by a contraction in CD11b+Ly6G−Ly6Chigh
cells (M-MDSCs) while sparing CD11b+Ly6G+Ly6Clow/int cells
(PMN-MDSCs). Furthermore, only those drugs effective in reducing
M-MDSCs eliminated the immune suppressive activity of cultured
cells on activated T lymphocytes (Fig. 1b). With a dose-response
curve similar to mouse BM-MDSCs, also human CD11bbright cells,
which mostly contain PMN-MDSCs, obtained by in vitro culture
from bone marrow (BM) Lin− cells in the presence of G-CSF and
GM-CSF for four days25, survived after exposure to different che-
motherapeutics (Supplementary Fig. 1d, e) at the expense of other
fractions and this led to loss of immune suppressive activity, as
shown for the drug 5-fluorouracil (Supplementary Fig. 1f).
To shed light on the possible mechanisms underlying the
cytotoxic action of the diverse chemotherapeutic drugs, we
treated MSC2 cells, an immortalized mouse MDSC line26, with
the minimal effective dose of one agent for each class. All tested
drugs activated caspases associated with extrinsic apoptotic
pathways, with similar but not overlapping kinetics (Supplemen-
tary Fig. 1g). Moreover, only the addition of a pan-caspase
inhibitor to 5-fluorouracil-treated MSC2 cells restored cell
viability, whereas no rescue was achieved with a necroptosis
inhibitor (Supplementary Fig. 1h). Considering the role of c-FLIP
in the survival of M-MDSCs but not PMN-MDSCs21, we
speculated that chemotherapeutics might modulate this anti-
apoptotic protein. Indeed, Ly6C+ cells purified from BM-MDSC
cultures after a 24 h treatment with M-MDSC-depleting drugs
downregulated the main c-FLIP isoforms, whereas drugs unable
to deplete M-MDSCs did not affect c-FLIP RNA expression
(Fig. 1c). These observations provide evidence for a correlation
between FLIP expression and chemotherapy susceptibility in
monocytes.
We next verified whether c-FLIP was associated with chemother-
apy resistance in human MDSCs. We modified a previously
described protocol25 to generate immunosuppressive MDSCs,
which could be infected in vitro by lentiviruses, by culturing BM-
derived stem cells (CD34+ cells) for four days in the presence of G-
CSF and GM-CSF. After the in vitro culture, CD34+ cells
differentiated into mature myeloid cells characterized by the
downregulation of the CD34 marker and acquisition of myeloid
lineage markers (CD33, CD11b, CD15, and CD14) (Supplementary
Fig. 2a). During differentiation, cells also acquired immunosup-
pressive functions typical of MDSCs27 (Supplementary Fig. 2b). We
next infected human CD34+ cells with lentiviral expression vectors
encoding the two major splice variants of human c-FLIP or
luciferase, as negative control, and cultured them in G-CSF and
GM-CSF in presence of 5-fluorouracil. The enforced expression of
c-FLIP prevented chemotherapy-dependent killing of more mature
myeloid cells (CD34− cells, Fig. 1d) and preserved their
immunosuppressive activity since 5-fluorouracil-treated, c-FLIP-
infected cells maintained their ability to arrest in vitro T cell
proliferation compared to the control (Fig. 1d).
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These data indicate that chemotherapy-driven elimination of
human MDSCs is dependent on c-FLIP modulation. Further-
more, compared to luciferase-expressing cells, untreated c-FLIP-
expressing CD34+ cells showed higher suppressive activity
toward activated T cells, which was still evident at inhibitor to
effector cell ratio as low as 0.1:1 (Fig. 1e). Therefore, c-FLIP not
only controlled myeloid cell survival but also modulated their
immune regulatory ability.
v-FLIP+ monocytes are chemotherapy-resistant and tolero-
genic. To dissect how FLIP proteins regulate myeloid cells we
next took advantage of a transgenic (Tg) mouse expressing a
form of FLIP from Kaposi’s sarcoma virus (hereafter called v-
FLIP)28. We crossed ROSA26.vFLIP knock-in mice with mice
expressing Cre recombinase under the control of the endogenous
Lyz2 promoter, thus resulting in mice with v-FLIP expression in
the myeloid lineage. In these mice, EGFP is expressed in a
common transcript with v-FLIP due to the insertion of an IRES
between the two gene sequences28. Tg mice (carrying both Cre
and v-FLIP genes) were born at the expected Mendelian fre-
quency but showed developmental abnormalities and all the mice
died within four weeks (Supplementary Fig. 3a, b). Indeed, Tg
mice developed a rapid and lethal cachexia associated with sys-
temic immune disorders: hematopoietic dysregulation (higher
absolute number of mature CD11b+Ly6G+Ly6Clow/int and
CD11b+Ly6G−Ly6Chigh cells), a systemic cytokine storm and
massive infiltration of myeloid cells in several organs (Supple-
mentary Fig. 3c–f), associated with a decrease in CD3+ T cells
and preservation of T regulatory (Treg) lymphocytes (Supple-
mentary Fig. 3g, h). Despite the short life span, these mice
allowed us to investigate the relationship between FLIP and
chemotherapy in a tumor-free environment. To this end, we
added the monocyte-depleting dose of 5-fluorouracil at the
beginning of in vitro culture with either wild type (WT) or Tg
BM cells and, after four days, determined the absolute numbers
of Ly6C+ monocytes. Cells with a higher intensity of GFP
expression (i.e., cells with higher expression of v-FLIP) survived
and were recovered following chemotherapy, compared to those
that displayed a lower intensity in GFP (Fig. 2a). Furthermore, v-
FLIP-BM-MDSCs retained some suppressive ability after the
chemotherapy treatment (Fig. 2b). We also observed that freshly
isolated, v-FLIP-expressing-Ly6C+ cells displayed an intrinsi-
cally higher suppressive ability compared to the WT monocytes
on a per cell basis while v-FLIP-expressing-Ly6G+ cells did not
show any statistically relevant enhancement in their
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Fig. 1 c-FLIP protects in vitro generated M-MDSCs from chemotherapy-induced death. a Representative flow cytometry plots of mouse BM-MDSCs after
chemotherapy treatment. Untreated Ly6C+ cells are in black squares; in red and in blue, Ly6C+ cells after exposure to the highest dose of chemotherapy
that maintains the cell viability (defined as ≥75% of AnnV-/7AAD- cells). b Suppressive activity of untreated (black bar) or chemotherapy-treated BM-
MDSCs (red bars indicate M-MDSC-affecting chemotherapeutics whereas blue bars indicate ineffective chemotherapeutics) was measured by CellTrace
dilution in peptide-activated CD8+ T cells. c Expression levels of both c-FLIPL and c-FLIPS in Ly6C+ cells purified from BM-MDSCs treated with different
chemotherapy were evaluated by real-time PCR. d Flow cytometry analysis of c-FLIP infected human in vitro generated BM-MDSCs (identified as CD34-
cells) after 5-fluorouracil treatment. e Functional assay on luciferase- and c-FLIP-infected BM-MDSCs derived from in vitro differentiation of hCD34+ cells,
either left untreated or after exposure to a M-MDSC-affecting dose of 5-fluorouracil. Data are presented either as mean ± s.e.m of three independent
experiments (b–e) or as a representative experiment of three independent experiments (a). *P < 0.05, **P < 0.01; ***P < 0.001; n.s., not significant, by
Mann–Whitney test
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immunosuppressive function (p= 0.235) (Fig. 2c). The differ-
ence between v-FLIP-expressing Ly6C+ and Ly6G+ cells was
also demonstrated in vivo. MCA205 tumor-bearing mice were
treated with anti-PD−1 mAb and, later, intravenously trans-
ferred with either fresh Ly6C+ or Ly6G+ cells isolated from the
BM of either Tg or WT mice. Only the adoptive cell transfer of v-
FLIP-expressing Ly6C+ cells was able to abrogate the checkpoint
inhibitor efficacy. On the contrary, the transfer of either v-FLIP-
expressing- or wild type Ly6G+ cells did not result in a statis-
tically significant change (p= 0.667 and p= 0.687, respectively)
(Fig. 2d and Supplementary Fig. 4a). The suppressive ability of
the fresh v-FLIP Tg monocytes was further confirmed in an ACT
experimental setting where the infusion of v-FLIP-expressing
Ly6C+ cells completely abrogated the therapeutic efficacy of
OVA-specific T cells in controlling EG7-OVA tumor progression
(Fig. 2e and Supplementary Fig. 4b). These data indicate that
unrestrained expression of v-FLIP, similarly to c-FLIP, is able to
confer chemotherapy resistance in Ly6C+ cells and reprogram
steady-state monocytes to present enhanced immunosuppressive
activity.
Human c-FLIP-engineered monocytes induce in vivo tolerance.
We next asked whether human mature monocytes could be
reprogrammed by c-FLIP expression to become
immunosuppressive. Starting from healthy donor (HD) buffy
coats, we purified and infected CD14+ monocytes with either c-
FLIP- or luciferase-encoding lentiviruses. Also in differentiated
CD14+ monocytes, c-FLIP expression increased suppressive
activity on stimulated T cells (Fig. 3a and Supplementary Fig. 5a).
The acquisition of this immune regulatory property did not
correlate with a better survival of c-FLIP-expressing monocytes
compared to controls, since the percentage of viable (7-AAD
−Annexin-V−) CD14+ cells after in vitro culture, either alone or
in the presence of activated T lymphocytes, was comparable
during the culture time (Supplementary Fig. 5b), indicating that
the immune regulatory activity can be separated from the anti-
apoptotic properties of c-FLIP, at least in the case of mature
monocytes. Moreover, the infection of CD14+ cells with lentiviral
vectors expressing different anti-apoptotic genes (Bcl-2 or Bcl-xL)
29,30 did not induce any functional ability to inhibit T cell pro-
liferation (Supplementary Fig. 5c, d). Therefore, FLIP is unique in
driving the acquisition of immunosuppressive program in
monocytes, which is not directly linked to longer survival.
Given the strong immune regulatory activity endorsed by FLIP
expression, we assessed the ability of c-FLIP-infected CD14+
monocytes to control the graft vs host disease (GvHD)
progression in a setting of xenogeneic transplantation. The
infusion of c-FLIP-transduced CD14+ cells, controlled estab-
lished GvHD, resulting in significantly improved long-term
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survival compared to both untreated mice and mice that received
luciferase-expressing CD14+ cells (Fig. 3b). The infusion of c-
FLIP-expressing monocytes also caused a contraction in the
number of circulating human CD3+ T cells, provoked the
expansion of Tregs and the impairment in IFN-γ production by
stimulated CD8+ T cells (Fig. 3c, d). The therapeutic impact of
the monocyte-induced immune modulation was confirmed by
histology and immunohistochemistry (IHC) analyses (Fig. 3e, f
and Supplementary Fig. 6a, b). Human CD14+ cell infiltration
was not detected in any of the analyzed tissues, excluding the
in vivo persistence of c-FLIP-infected cells after their infusion
(Supplementary Fig. 6c). Importantly from a clinically relevant
translational viewpoint, frozen c-FLIP-expressing monocytes
retained their immune modulating activity after thawing and
injection in mice; in fact, established GvHD progression was
better controlled by the engineered monocytes when compared to
thawed human Tregs (Supplementary Fig. 6d–f).
FLIP activates a broad inflammatory pathway in myeloid cells.
To investigate the molecular events triggered by enforced c-FLIP
expression, we analyzed the transcriptomes of c-FLIP- and
luciferase-infected CD14+ cells (GSE101587). The supervised
clustering (q.val < 0.05; fold change >2) indicated more than 1100
upregulated genes associated with immune regulation in c-FLIP-
infected monocytes compared to control. The list included
SOCS2, FAS, CCR7, CCL5, STAT3, CD38, CD274, PDCD1LG2,
IL6, IL10, CFS3, PTGS2, IDO1, and IDO2 that are normally
activated in MDSCs27 (Fig. 4a). By using the gene set enrichment
analysis (GSEA), the differentially expressed genes were sig-
nificantly enriched in categories involved in inflammation, cyto-
kine network and genes up-regulated in response to interferon
proteins, as well as associated to the IL-10 pathway and, overall,
to NF-κB-related pathway (Fig. 4b); these categories were con-
firmed also by gene ontology (GO) enrichment analysis (Sup-
plementary Fig. 7a, b). We proved that c-FLIP-transduced
CD14+ cells did upregulate both c-FLIP isoforms, i.e. c-FLIPL
and c-FLIPS, as well as IDO1, and secreted higher amounts of IL-
10 and metabolites of IDO1 enzymatic activity, i.e. kynurenine,
when compared to luciferase-transduced CD14+ cells. Further-
more, c-FLIP-expressing monocytes upregulated the surface
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Fig. 3 c-FLIP-engineered monocytes transfer controls GvHD progression. a Immunosuppressive functions of CD14+ monocytes freshly isolated from buffy
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molecules PD-L2, PD-L1, and CD38, validating gene expression
analysis and highlighting a MDSC-like profile (Fig. 4c).
The enforced expression of FLIP triggers NF-κB pathway. Gene
expression data suggested a previously unpredicted transcrip-
tional and signaling activity of c-FLIP, possibly linked to the NF-
κB pathway. To elucidate the molecular programs under c-FLIP
control, we transiently transfected THP1 monocytic cell line with
in vitro transcribed (IVT) c-FLIP-encoding RNA. The rational
was to induce a sustained and viral-independent production of
the target protein; moreover, the IVT-RNA does not activate
innate immunity receptors and type I interferon production31.
Enforced introduction of a synthetic c-FLIP RNA in THP1 cells
triggered an immunosuppressive program consistent with the
data shown thus far with lentivirus expression vectors (Fig. 5a
and Supplementary Fig. 8a). Transfection of c-FLIP RNA sig-
nificantly promoted the nuclear translocation of the NF-κB
subunits p65 and p50, mediators of the canonical NF-κB acti-
vation pathway, while no difference in the p52 subunit translo-
cation was detected (Fig. 5b and Supplementary Fig. 8b). The
kinetics of protein translocation to nucleus and the activation of a
reporter gene in THP1-Blue™ cell line induced by c-FLIP RNA
transfection demonstrated a strong signaling (with a top activity
at 18 h) even though the c-FLIP cytoplasmic localization peaked
at 6 h after transfection (Supplementary Fig. 8c). Unexpectedly,
we observed c-FLIP nuclear translocation (Fig. 5c) and, more
interestingly, a nuclear co-localization between c-FLIP and p50
(Fig. 5d), which might underlie the gene expression induced by
FLIP-enforced expression. Also in freshly isolated, v-FLIP-
expressing myeloid cells (Ly6C+ and Ly6G+ cells) we detected
a significant nuclear translocation of p65 and p50 proteins
compared to WT cells, especially within the monocytic subset
(Supplementary Fig. 8d). These data indicate that v-FLIP sig-
naling modules are shared with c-FLIP and depend on NF-κB
activation in monocytes. To test whether NF-κB signaling was
required for the immune regulatory program downstream of
FLIP, we demonstrated the ability of NF-κB pathway chemical
inhibitors (TPCA-1 and 5Z-7-oxozeanol) to abrogate the
immunosuppressive activity of v-FLIP-expressing CD11b+Ly6C+
cells isolated from Tg mice and induce a strong downregulation
of membrane PD-L1 (Supplementary Fig. 9a, b). To provide
additional, causative evidence that FLIP-driven immunosup-
pression is mediated by NF-κB, we silenced the kinases IKKα
(encoded by Chuk) and IKKβ (encoded by Ikbkb), alone or in
combination (Supplementary Fig. 9c) both indispensable for
canonical NF-κB activation. We demonstrated that interference
with NF-κB pathway was able to restrain partially the immuno-
suppressive activity as well as the PD-L1 expression in CD11b
+Ly6C+ cells isolated from either BM of Tg mice (Supplementary
Fig. 9d, e) or spleen of tumor-bearing wild-type mice (Fig. 5e, f
and Supplementary Fig. 9f). Collectively our data indicate that
FLIP activates a signaling pathway that controls the immuno-
suppressive program in monocytes in part through canonical NF-
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κB activation, which directly drives PD-L1 expression. We thus
confirm and extend the assumption, supported by longstanding
experiments on T lymphocytes, about a direct NF-κB activation
by c-FLIP, independent from its anti-apoptotic activity32.
FLIP-expressing monocytes in patients with pancreatic cancer.
We assessed c-FLIP expression in blood circulating CD14+
monocytes, by intracellular staining in combination with surface
detection of PD-L1, PD-L2, and CD38 (Supplementary Fig. 10a).
We evaluated cohorts of treatment naïve PDAC (n= 25) and
neuroendocrine tumor (NET, n= 5) patients and HDs (patients
on oral anticoagulant treatment, n= 25), as a control. Compared
to HD, there was a significant increase in the percentage of
c-FLIP+CD14+ cells in PDAC but not in NET patients (Fig. 6a),
suggesting that c-FLIP might constitute a biomarker for some
cancers. Furthermore, heightened surface expression of PD-L1,
PD-L2, and CD38 markers was detected in the cell subset iden-
tified as c-FLIP+CD14+ cells, in agreement with our data with
genetically-engineered monocytes (Fig. 6b, c and Supplementary
Fig. 10b). We evaluated the presence of FLIP-expressing mono-
cytes in frozen PBMCs of a second, independent PDAC patient
cohort (n= 71) based on the following inclusion criteria: resected
pancreatic cancers and treatment naive (Supplementary Tables 1
and 2). Association between the percentage of c-FLIP+CD14+
cells, overall survival (OS) and disease-free survival (DFS) was
explored: a positive, but not statistically significant correlation
was observed, probably dependent on the sample size (Supple-
mentary Fig. 10c). However, we demonstrated that PDAC
patients with a higher percentage of c-FLIP+PD-L1+CD14+ cells
had significantly shorter OS (p= 0.024) and DFS (p= 0.014)
while there was a less significant relationship between FLIP+PD-
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L2+CD14+ cells, OS and DFS in the same cohort (Fig. 6d).
Moreover, a statistically significant correlation was found between
the combination of high level of serum IL-6 in conjunction with
the frequency of c-FLIP+PD-L1+CD14+ cells and poor OS (p=
0.0014) and DFS (p= 0.036, Fig. 6e). PD-L1+ expression (Sup-
plementary Fig. 10d) and IL-6 serum levels alone33 were only
predictive for the OS, but not for DFS; instead, PD-L2+ expres-
sion (Supplementary Fig. 10e) was not predictive for both OS and
DFS. Finally, a multivariate analysis indicated that tumor grade
G3 and high IL-6/c-FLIP+PD-L1+CD14+ cells were negative
independent prognostic factors for both OS and DFS in this
patient’s cohort (Supplementary Table 3).
Discussion
FLIP is an anti-apoptotic regulator that is involved in conferring
chemotherapeutic resistance in a wide range of cancers34. Our
data highlight an inverse correlation between FLIP expression
and chemotherapy susceptibility in tolerogenic M-MDSCs both
in vivo and in vitro. Tumor-conditioned monocytes, in fact, are
so dependent on c-FLIP expression for their survival to be poi-
soned by treatments reducing the protein expression. We used
low doses of different chemotherapeutic drugs, belonging to four
classes with diverse mechanisms of action: anti-metabolite agents
(5-fluorouracil, gemcitabine), mitotic inhibitors (docetaxel,
paclitaxel), alkylating agents (oxaliplatin, cisplatin) and topoi-
somerase inhibitors (etoposide, irinotecan). All these drugs
selectively affected BM-MDSC differentiation, causing a con-
traction in M-MDSCs (CD11b+Ly6C+ cells) and loss of immu-
nosuppression via the extrinsic apoptotic pathway, except for
fludarabine and carboplatin. Indeed, fludarabine mainly induces
apoptosis via a mitochondria-dependent pathway35 whereas
carboplatin alone has no effect on apoptosis, while it triggers
apoptosis via caspase-3 activation in combination with thior-
idazine36. The M-MDSC depletion is mediated by the activation
of the caspases cascade belonging to the extrinsic apoptotic
pathway and we showed here for the first time, to the best of our
knowledge, that c-FLIP is the downstream target of different
chemotherapeutics. PMN-MDSCs are likely protected by the
exposure to M-MDSC-depleting chemotherapeutics since they do
not constitutively require c-FLIP expression for their survival,
which instead depends upon Mcl-121.
In addition to influencing cell survival, we clearly defined that
c-FLIP directly regulates the tolerogenic properties of monocytes,
in part through activation of the canonical NF-κB signaling
pathway. Since other anti-apoptotic proteins, such as Bcl-2 and
Bcl-xL, are not capable of activating this molecular program, we
speculate that FLIP-associated immunosuppression in monocytes
is not directly linked to a prolonged survival and thus unveils a
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previously unrecognized function for this protein. Mouse and
human FLIP-expressing monocytes acquired immunosuppressive
features able to constrain T cell activation, both in vitro and
in vivo. Furthermore, our experiments using a Tg mice, in which
the v-FLIP expression was restricted to myeloid cells, demon-
strated that FLIP activation during myeloid differentiation
induces a severe inflammatory pathology characterized by an
unrestrained systemic myeloid cell infiltration that represses B
and T cells, resembling the human inflammatory cytokine syn-
drome (either associated or not with multicentric Castelman
disease), a rare heterogeneous disease in part related to Kaposi’s
sarcoma herpesvirus infection and characterized by an excess of
IL-6 secretion28. Interestingly, higher IL-6 serum levels and blood
circulating c-FLIP+CD14+PD-L1+ monocytes defined the PDAC
patients with worse survival.
Beside the pro-inflammatory gene signature, c-FLIP also
affected immune regulatory pathways consisting of more than
1100 upregulated genes, which are enriched in categories involved
in NF-κB response to TNF, cytokine network, and genes upre-
gulated by IL-6 via STAT3. This specific gene signature may be
linked to a “steered” NF-κB activation induced by the nuclear
translocation of FLIP. Moreover, the FLIP-associated signature
clustered healthy individuals and cancer patients, reflecting the
potential involvement of c-FLIP in cancer-induced inflammation.
The enumeration of circulating c-FLIP-expressing monocytes, in
association with specific surface markers induced by FLIP, such as
PD-L1, PD-L2 and CD38 can thus constitute a useful tool to
refine the immunological landscape of cancer patients for a more
correct diagnosis and treatment. Obviously, it would be impor-
tant to exploit the efficacy of these markers in cancer settings
other than PDAC.
A careful analysis of the growth curves in tumor-bearing mice
treated with anti-PD-1 suggest that PD-L1 expression can be
responsible only for a part of the immune evasion mediated by
the infusion of v-FLIP-expressing monocytes (Supplementary
Fig. 4a). Considering the plethora of immune regulatory circuits
activated by FLIP, this was largely expected. Our data suggest that
targeting FLIP-associated monocytes in combination with
checkpoint inhibitors might increase the therapeutic efficacy of
cancer immunotherapy.
By contrast to cancer, where depletion of immunosuppressive
myeloid cells is sought, the infusion of engineered, FLIP-
expressing monocytes might help treating patients with severe
GvHD, with clinical advantages over other immunoregulatory
cells, such as Tregs. Several reports suggest the potential effect of
MDSC-like cells on GvHD control37. In a mouse GvHD model, a
single early, post-transplant MDSC infusion transiently sup-
pressed but did not eliminate GvHD38. This limited activity likely
depends on the infusion of incompletely differentiated myeloid
cells, which survive in the host after transfusion and differentiate
in vivo into antigen presenting cells (APCs), thus limiting the
treatment effectiveness. The M-MDSC subset comprises cycling
and partially committed precursors9 that can lose their immu-
nosuppressive ability following activation of AIM2 inflamma-
some38. In our experiments, the therapeutic effect of FLIP-
expressing human CD14+ cells was assessed in a stringent
experimental model of established GvHD. In fact, infusions of
myeloid cells were started when the disease was clearly detected
(circulating hCD3+ T cells >5%). FLIP-expressing, human
CD14+ cells did not survive in vivo for a long time after transfer,
limiting their potential to mature into APCs able to sustain T cell
activation. We think that all these combined effects allowed
reconditioned hCD14+ monocytes to control disease progression
in the host.
We have uncovered a critical dual role of FLIP in myeloid cell
physiology. In mature monocytes, cancer-induced FLIP
expression promotes immune suppressive functions, prolongs
survival and confers chemotherapy susceptibility; on the other
hand, constitutive FLIP activation in myeloid lineage fuels a
chronic inflammatory syndrome associated with myeloprolifera-
tion and immune suppression. Hence, FLIP emerges as a novel
candidate for controlling cancer-associated chronic inflammation
and immune dysfunction, as well as a target to generate powerful
immune modulators of exaggerated, life-threatening immune
responses.
Methods
Mice. NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac (NOG) mice were purchased from
Taconic Biosciences (Hudson, NY, USA). C57BL/6J mice were purchased from
Charles River Laboratories Inc (Calco, Italy). OT-1 TCR-transgenic mice (C57BL/
6-Tg(TcraTcrb)1100Mjb/J) and CD45.1+ congenic mice (B6.SJL-PtrcaPepcb/BoyJ)
were from Jackson Laboratories (Bar Harbor, ME, USA). Rosa26.vFLIP mice were
a gift from Dr. Ethel Cesarman (Weill Cornell Medicine, NY, USA), LysM-CRE
mice were a gift from Dr. Patrizia Scapini (University of Verona, Verona, Italy). All
mice were maintained under specific pathogen-free conditions in the animal
facilities of the University of Verona. Animal experiments were performed
according to national (protocol number 12722 approved by the Ministerial Decree
Number 14/2012-B of January 18, 2012 and protocol number BR15/08 approved
by the Ministerial Decree Number 925/2015-PR of August 28, 2015) and European
laws and regulations. All animal experiments were approved by Verona University
Ethical Committee (http://www.medicina.univr.it/fol/main?ent=bibliocr&id=85)
and conducted according to the guidelines of Federation of European Laboratory
Animal Science Associations (FELASA). All animal experiments were in accor-
dance with the Amsterdam Protocol on animal protection and welfare: mice were
monitored daily and euthanized when displaying excessive discomfort.
Human samples. CD34+ cells isolated from BM were purchased by AllCell
(Alameda, CA, USA). Lin− cells were isolated from fresh BM aspirate samples with
normal cytological characteristics, obtained from patients undergoing surgical
implants in the Orthopaedic Clinic. The project was approved by the local Ethics
Committee (2014/101 on 15/12/2014 [PI]: S.M.) and all patients gave their
informed consent. PBMCs isolated from either PDAC and NET patients or Healthy
Donors (HD) were collected by informed consent to biobank prior the study (Prot.
52070, Prog. 1885 on 17/11/2010, principal investigator [PI]: A.S.) and the study
was approved by the Ethics Committee (Prot. 25978, Prog. 2172 on 29/05/2012,
principal investigator [PI]: A.S.).
Indeed, 287 patients admitted at the Unit of General and Pancreatic Surgery of
the Azienda Ospedaliera Universitaria Integrata of Verona between 2012 and 2014
with suspected PDAC were assessed for eligibility. Among them, a total of 71
treatment-naïve resectable patients with histologically proven non-metastatic
PDAC were included in the study. Inclusion criteria for this study were:
histopathological confirmation of PDAC, no prior neo-adjuvant therapy, no
evidence of metastatic disease, eligible for surgical resection. Peripheral blood
samples were prospectively collected from all patients before surgical resection.
Clinic-pathologic features of patients were reported in Supplementary Table 2 and
included age, gender, tumor location, tumor size, differentiation status, lymph node
involvement and TNM stage, patterns of resection margins, patterns of recurrence.
Disease-free survival (DFS) was determined from the time of surgery until local or
metastatic PDAC tumor recurrence. Overall survival (OS) was defined as the time
of surgery to death. Informed consent was obtained from all subjects. This study
was performed in accordance with the ethical standards of the Helsinki Declaration
of the World Medical Association. Compliance with REMARK guidelines is
reported in Supplementary Table 1. Survival curves were drawn by Kaplan-Meier
estimates and compared by log-rank test. The optimal cutoff thresholds of
biomarkers were obtained based on the maximization of the Youden’s statistics J=
sensitivity+ specificity+ 1 using an R-based software as described in Budczies
et al.39. Multivariate analyses were conducted by Cox’s proportional hazard
regression models using all variables that were significant in univariate analysis
(p ≤ 0.05). Statistical analyses were performed using GraphPad Prism software
program (version 5.00 for MAC OS X, GraphPad Software, San Diego, California
USA, www.graphpad.com), IBM SPSS Statistics (version 24.0 Armonk, NY: IBM
Corp.), and the statistical language R.
Cell lines. Chicken ovalbumin (OVA)-transfected EL-4 (EG7) cell line derived
from C57BL/6J mice and human embryonic kidney cell line 293 (HEK293, ATCC®
CRL-1573™, LGC Standards S.r.l., Milano, Italy), THP-1 cell line (ATCC® TIB-
202™, LGC Standards S.r.l., Milano, Italy), THP1-Blue™ NF-κB cell line (InvivoGen,
CA, USA), MCA203 cell line, a fibrosarcoma induced by 3-methylcholanthrene (a
kind gift by Prof. M.P.Colombo) and MCA205 cell line, a mouse sarcoma (a kind
gift by Prof. L. Zitvogel) were grown in DMEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 2 mM L-glutamine (Euroclone, Milano, Italy), 10 mM HEPES
(Euroclone, Milano, Italy), 20 µM β-mercaptoethanol (Sigma-Aldrich, Saint Louis,
MO, USA), 150 U/ml streptomycin (Euroclone, Milano, Italy), 200 U/ml penicillin
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07654-4 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5193 | DOI: 10.1038/s41467-018-07654-4 | www.nature.com/naturecommunications 9
(Euroclone, Milano, Italy) and 10% heat-inactivated fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA). MSC2 is an immortalized cell line derived from
Balb/c mice26 and it was cultured in RPMI 1640 (Life Technologies, Carlsbad, CA,
USA) supplemented with 2 mM L-glutamine (Euroclone, Milano, Italy), 10 mM
HEPES (Euroclone, Milano, Italy), 150 U/ml streptomycin (Euroclone, Milano,
Italy), 200 U/ml penicillin (Euroclone, Milano, Italy) and 10% heat-inactivated FBS
(Superior, Merck, Darmstadt, Germany). All cell lines were tested to be free from
Mycoplasma contamination by PCR screening.
Cytokines, synthetic peptides, reagents, and chemotherapeutic drugs. Mouse
recombinant GM-CSF, mouse recombinant IL-6, human recombinant GM-CSF,
and human recombinant G-CSF were purchased from Miltenyi Biotec (Bologna,
Italy). Kb-restricted OVA257–264 peptide (SIINFEKL), was synthesized by JPT
(Berlin, Germany). Necrostatin-1, 5Z-7-Oxozeaenol (253863) and TPCA-1
(507475-17-4) were purchased from Sigma-Aldrich (Saint Louis, MO, USA) and
pan caspase Inhibitor (Z-VAD-FMK) from R&D Systems (Minneapolis, MN,
USA). InVivoMAb anti-mouse PD-1 (RMP1-14) and isotype control (2A3) were
purchased from Bioxcell (Lebanon, NH, USA). Chemotherapeutic drugs: 5-
fluorouracil (51-21-8); gemcitabine (95058-81-4); docetaxel (114977-28-5); pacli-
taxel (33069-62-4); oxaliplatin (61825-94-3); cisplatin (15663-27-1), etoposide
(33419-42-0), irinotecan (100286-90-6), fludarabine (21679-14-1) and carboplatin
(41575-94-4) were purchased by Cayman Chemical (Ann Arbor, MI, USA).
Mouse proliferation assay. The immunosuppressive activity was evaluated plat-
ing in vitro differentiated MDSC or freshly isolated myeloid cells from ROSA26.
vFLIP mice in 96 wells plate at a final concentration of 24% of total cells in culture
in presence of splenocytes from OT-I transgenic mice, labeled with 1 μM CellTrace
(Thermo Fisher Scientific, Waltham, MA, USA) and diluted 1:10 with CD45.1+
splenocytes, in the presence of SIINFEKL peptide (1 μg/ml final concentration).
After 3 days of co-culture, cells were stained with APC-Cy7 conjugated anti-
CD45.2 (clone 104, eBioscience, Thermo Fisher Scientific, Waltham, MA, USA)
and PerCP-Cy5.5 conjugated anti-CD8 (clone SK1, eBioscience, Thermo Fisher
Scientific, Waltham, MA, USA). CellTrace signal of gated lymphocytes was used to
analyze cell proliferation. Samples were acquired with FACS-Canto II (BD,
Franklin Lakes, NJ, U.S.A.) using TruCountTM tubes (BD, Franklin Lakes, NJ,
USA) to determine the absolute cell number of CD8+ cells in the samples. Data
were analyzed by FlowJo software (Tree Star, Inc. Ashland, OR, USA).
Human proliferation assay. PBMCs were isolated from leukocyte-enriched buffy
coats from the healthy volunteer (Transfusion Center, University and Hospital
Trust of Verona, Verona, Italy) by Ficoll-Hypaque (GE Healthcare, Uppsala,
Sweden) gradient centrifugation as described above. The use of PBMC was
approved by the ethical Ethic Board of the Azienda Ospedaliera Universitaria
Integrata of Verona(AOUI) (protocol numbers: 24114 on 16/05/2017, principal
investigator [PI]: V.B.). PBMCs were then counted, frozen at −80 °C and stored in
liquid nitrogen. PBMCs were recovered and washed in IMDM medium (Lonza,
Visp, Switzerland), supplemented with 10% FBS (Euroclone, Milano, Italy), 100U/
ml penicillin/streptomycin (Euroclone, Milano, Italy), β-mercaptoethanol (Sigma-
Aldrich, Milan, Italy) and 10 mM HEPES (Euroclone, Milano, Italy). PBMCs were
resuspended at a final concentration of 107 cells/ml in PBS and stained with 2,5 μM
as final working concentration of CellTrace Violet stock solution (Thermo Fisher
Scientific, Waltham, MA, USA), followed by 5 min’ incubation at 37 °C, protected
from light. Cells were then washed and resuspended in culture medium. Labeled
“target” PBMCs were stimulated with coated 0.6 μg/ml anti-CD3 (clone OKT-3,
eBioscience, Thermo Fisher Scientific, Waltham, MA, USA) and 5 μg/ml soluble
anti-CD28 (clone CD28.2, eBioscience, Thermo Fisher Scientific, Waltham, MA,
USA) for four days and co-cultured with “effectors” CD34+ or CD14+ cells at
0.1:1, 0.5:1, 1:1, 2:1, 3:1 ratio (effector: target) in 384 flat bottom well plates (BD,
Franklin Lakes, NJ, USA). Cell cultures were incubated at 37 °C and 5% CO2 in
arginine and glutamine–Free-RPMI (Biochrom AG, Berlin, Germany), supple-
mented with 2 mM L-glutamine (Euroclone, Milano, Italy), 150 μM arginine
(Sigma-Aldrich, St. Louis, MO, USA), 10% FBS (Superior, Merck, Darmstadt,
Germany), 10 U/ml penicillin and streptomycin (Euroclone, Milano, Italy), and
0.1 mM HEPES (Euroclone, Milano, Italy). At the end of the culture, cells were
stained with PE-Cy7 conjugated anti-CD3 (UCHT1, eBioscience, Thermo Fisher
Scientific, Waltham, MA, USA), and CellTrace signal of gated lymphocytes was
analyzed. TruCountTM tubes (BD, Franklin Lakes, NJ, USA) were used to deter-
mine the absolute cell number of CD3+ cells in the samples. Data were analyzed by
FlowJo software (Tree Star, Inc. Ashland, OR, USA).
Immunomagnetic human monocytes isolation. Human CD14+ monocytes were
isolated by immunomagnetic sorting (Miltenyi Biotec, Bologna, Italy) according to
the manufacturer’s instructions and their purity was evaluated by flow cytometry
using a mouse anti-human mAb.
Plasmid vectors. Lentiviral transduction vectors pELNS encoding c-FLIPS-GFP,c-
FLIPL-GFP, Bcl-2, and Bcl-xL were a kind gift from Prof. G. Coukos (Department
of Oncology, Ludwig Cancer Research Center, University Hospital of Lausanne
(CHUV), Lausanne, Switzerland)17. Lentiviral transduction vector pELNS
encoding luciferase was a kind gift from Dr. D. Melisi (University of Verona). We
sub-cloned viral FLIP using plasmids available from Addgene (Cambridge, MA,
USA) and then the target sequence into pELNS vector.
RNA synthesis. The sequences encoding for GFP, c-FLIPS, c-FLIPL, v-FLIP, eGFP-
(2TA)-c-FLIPS, eGFP-(2TA)-c-FLIPL, eGFP-(2TA)-v-FLIP were subcloned in the
pST-T7-hAg-MCS-FI-A30LA70 vectors and IVT mRNA were produced as pre-
viously described31,40. The 3′ UTR (F-I) of this construct have been shown to
enhance stability and translation efficiency, as it has the 100-nucleotide poly(A) tail
interrupted by a short linker. Plasmids were linearized with EarI and served as the
template for IVT mRNA synthesis using T7 RNA polymerase and a transcription
kit (MegaScript, Ambion, Austin, TX, USA). The UTP in the reaction was replaced
with 1-methylpseudouridine triphosphate (N1-methylpseudouridine-5′-tripho-
sphate, m1ΨTP) (TriLink). β-S-ARCA(capD1) IVT mRNAs were generated as
described elsewhere41. Upon IVT mRNA production, single-stranded RNA was
enriched by cellulose purification and the absence of double-stranded RNA
(dsRNA) was confirmed using the dsRNA-specific mAb J2 (10010200, English and
Scientific Consulting)31. The quality of the purified dsRNA-free IVT mRNA was
assessed by spectrophotometry on a 2100 Bioanalyzer (Agilent), and the mRNA
was stored at −80 °C.
RNA transfection. THP1 RNA-transfection was performed with the following
protocol: THP1 were transfected with GFP, c-FLIPS-GFP, c-FLIPL-GFP, c-FLIPS-
GFP+ c-FLIPL-GFP (50+ 50%), v-FLIP-GFP mRNAs using VIROMER RED
technology (Lipocalyx, Halle, Germany) according to the supplier instructions: 3 ×
106 THP1 cells were seeded in a well of a 6-well plate at a concentration of 2.5 ×
106/ml and received 300 μl of a transfection mix composed by 270 μl of mRNA in
Viromer Red buffer (11 ng/μl) and 30 μl of Viromer Red solution (diluted 1/25 in
Viromer Red Buffer). For mouse monocyte transfection the following protocol was
used: after immuno sorting, 1 × 106 Ly6C monocytes were transfected in 1 ml of
RPMI 1640 (Life Technologies, Carlsbad, CA, USA) for 4 h with IKKα, IKKβ, or
scramble siRNAs using gene silencer technology (GenLantis, San Diego, CA, USA).
4 h post transfection 0.5 ml of media was added. The next day, transfected Ly6C
were tested in vitro for their suppressive ability.
Lentivirus production and infection. Self-inactivating replication of viral particles
were produced by calcium phosphate-mediated transfection of packaging cells
(HEK293T) with the appropriate amounts of transfer plasmid and HIV-1 lentiviral
packaging constructs pDEL, pREV, and VSV-G. Supernatants were harvested 48 h
after transfection, 0.22 μm filtered, concentrated by ultracentrifugation (50,000 × g;
2,20 h), and titrated by limiting dilution assay in HEK293T.
Human CD34+ cells were infected at a MOI (multiplicity of infection) of 2 with
8 µg/ml of polybrene (Millipore, Billerica, MA, USA) and cultured overnight in a
37 °C incubator at 8% CO2. Virus-containing media was then removed and
replaced with fresh one supplemented with cytokines (G-CSF and GM-CSF at
40 ng/ml each). The cells were then differentiated for 4 days. Human CD14+ cells
were infected at a MOI of 1 with 8 µg/ml of polybrene (Millipore, Billerica, MA,
USA) for 4 h by spin-inoculation (2000 rpm; 37 °C). Transduced cells received
fresh media and were incubated overnight in a 37 °C incubator at 5% CO2.
Real-time PCR. Total RNA from both c-FLIP or luciferase- infected monocytes
were isolated by TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA).
The amount and purity of isolated RNA was analyzed by the ND-1000 Spectro-
photometer (NanoDrop Technologies). cDNA was prepared using the Super-
Script® VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instruction. Real Time PCR was run using 2x SYBR Green
master mix (ABI). All samples were normalized using GAPDH endogenous control
primers. Post-qRT-PCR analysis to quantify relative gene expression was per-
formed by the comparative Ct method (2−ΔΔCt).
Gene expression. For microarrays of genes regulated by c-FLIP overexpression,
we prepared n= 4 biological replicates of c-FLIP overexpressing cells and n= 7
controls. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Ger-
many), and contaminant DNA was removed by RNase-Free DNase Set (Qiagen,
Hilden, Germany). RNA quality and purity were assessed on the Agilent Bioana-
lyzer 2100 (Agilent Technologies, Milano, Italy); RNA concentration was deter-
mined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies). As control of effective gene modulation and of the whole procedure,
we monitored the expression levels of c-FLIP by qPCR prior to microarray
hybridization. Labeling and hybridization were performed according to Affymetrix
One Cycle Target Labeling protocol on HG-U133 Plus 2.0 arrays (Affymetrix,
Thermo Fisher Scientific, Waltham, MA, USA). Microarray data are available at
Gene Expression Omnibus under accession GSE101587 (see also Supplementary
Dataset_1).
All data analyses were performed in R (version 3.3.1) using Bioconductor
libraries (BioC 3.5) and R statistical packages. Probe level signals were converted to
expression values using robust multi-array average procedure RMA42 of
Bioconductor affy package and batch-corrected using the ComBat function of
Bioconductor sva package. To identify genes associated with c-FLIP overexpression
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in CD14+ cells (c-FLIP signature), we compared the expression levels of CD14+
cells transfected with c-FLIP with those of control cells using Significance Analysis
of Microarray algorithm coded in the same R package43. In SAM, we estimated the
percentage of false-positive predictions (i.e., false discovery rate, FDR) with 100
permutations and selected as differentially expressed those probe sets with an FDR
q-value ≤0.01 and an absolute fold change ≥2. This selection resulted in 1690 probe
sets corresponding to 486 unique genes upregulated by c-FLIP (c-FLIP signature;
GSE101587) and 523 unique downregulated genes. To functionally annotate genes
induced by c-FLIP, we consider the Biological Process Gene Ontology (GO)
categories and the GO over-representation test44 implemented in the Bioconductor
cluster Profiler package. GO terms were considered significant at a confidence level
of 95% after p-value correction using the Benjamini–Hochberg (BH) procedure.
Over-representation analysis was performed using Gene Set Enrichment
Analysis and gene sets of the Biocarta and Hallmark collections from the Broad
Institute Molecular Signatures Database (http://software.broadinstitute.org/gsea/
msigdb). GSEA software (http://www.broadinstitute.org/gsea/index.jsp) was
applied on log2 expression data of cells transfected with c-FLIP or with control
vector. Gene sets were considered significantly enriched at FDR <5% when using
Signal2Noise as metric and 1000 permutations of gene sets.
Average signature expression has been calculated as the standardized average
expression of all signature genes in sample subgroups. Signature scores have been
obtained summarizing the standardized expression levels of signature genes into a
combined score with zero mean45. The values shown in graphs are thus a
dimensional.
Elisa assays. ELISA for human IL-10 (eBioscience, Thermo Fisher Scientific,
Waltham, MA, USA), ProcartaPlex Mouse Cytokine & Chemokine Panel 1A (36
plex: IFN-γ; IL-12p70; IL-13; IL-1β; IL-2; IL-4; IL-5; IL-6; TNF-α; GM-CSF; IL-18;
IL-10; IL-17A; IL-22; IL-23; IL-27; IL-9; GRO-α; IP-10; MCP-1; MCP-3; MIP-1α;
MIP-1β; MIP-2; RANTES; Eotaxin; IFNα; IL-15/IL-15R; IL-28; IL-31; IL-1α; IL-3;
G-CSF; LIF; ENA-78/CXCL5; M-CSF) (eBioscience, Thermo Fisher Scientific,
Waltham, MA, USA) and Bio-Plex Pro Human cytokine standards group II (23-
Plex: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12p70, IL-13, IL-15, IL-17a,
eotaxin, IL-1Rα, G-CSF, GM-CSF, IFN-γ, IP10, CCL2, CCL3, CCL4, TNFα, and
VEGF) were performed according to manufacturer’s instructions.
Kynurenine quantification. IDO1 enzymatic activity was measured in vitro in
terms of the ability of c-FLIP or luciferase-infected monocytes—incubated for 6 h
in a medium supplemented with 100 µM L-Tryptophan (73-22-3; Sigma-Aldrich,
Saint Louis, MO, USA)—to metabolize tryptophan to kynurenine, whose con-
centrations were measured by high performance liquid chromatography (HPLC) in
culture supernatants. The detection limit of the assay was 0.05 µM.
Western blot. Cell lysates were made in RIPA buffer with the addition of protease
inhibitor cocktail tablets (Roche, Monza, Italy) and sodium vanadate. Insoluble
material was removed by centrifugation. SDS-PAGE was done on 12% denaturing
SDS polyacrylamide gel and transferred on PVDF membrane (Millipore, Billerica,
MA, USA). Membranes were blocked in Tris-buffered saline plus 0.05% Tween-20
and 5% non-fat milk. We used the following antibodies: anti-mouse caspase-3
(D3E9), caspase-7 (D6H1), caspase-8 (D35G2) and caspase-9 (D2D4), anti-human
p65 (D14E12), p50 (D7H5M), p52 (18D10), H3 (D1H2), anti-FLIP (D5J1E) pur-
chased from Cell Signaling Technologies (Danvers, MA, USA), followed by incu-
bation with the secondary goat anti-rabbit IgG antibody, horseradish peroxidase
(HRP)-conjugated (Millipore, Billerica, MA, USA). Uncropped images of immu-
noblots displayed in the figures are in the Supplemntary information section
(Supplementary Fig. 11).
Flow cytometry. Sample tubes were washed in phosphate-buffered saline (PBS)
and incubated with 2 µl of FcReceptor Blocking reagent (Miltenyi Biotec, Bologna,
Italy) for 10 min at 4 °C to saturate FcR. The following mAbs (1 µl) were then used
for cell labeling: anti-mouse CD11b (M170), Ly6C (HK1.4), Ly6G (RB6-8C5), B220
(RA3-6B2), CD3 (145-2C11), CD8 (SK1), CD45.2 (104), CD4 (RM4−5), CD25
(BC96), FoxP3 (3G3), Ter-119 (TER-119), CD117 (2B8), IL7RA (A7R34), SCA-1
(D7), CD32 (6C4), CD34 (RAM34); anti-human CD34 (4H11), CD33 (WM53),
CD14 (61D3), CD13 (L138), CD15 (MMA), CD16 (3G8), CD11b (ICRF44),
CD117 (104D2), CD3 (UCHT1), CD274 (MIH1), CD38 (HIT2), CD273 (MIH18),
CD124 (25463), HLA-DR (L243), CD4 (SK3), CD8 (RPA-T8), CD25 (BC96),
FoxP3 (259D/C7), IFNγ (B27). All antibodies were purchased from the following
companies: BD Biosciences (San Jose, CA, USA), eBiosciences (Thermo Fisher
Scientific, Waltham, MA, USA), Biolegend (San Diego, CA, USA) and Cell Sig-
naling Technologies (Danvers, MA, USA). Samples were acquired with a FACS-
Canto II (BD, Franklin Lakes, NJ, USA) and analyzed with FlowJo software
(Treestar Inc.).
FLIP protein expression was evaluated by flow cytometry by indirect
amplification on intracellular signal. In details, after surface markers staining, 1 ×
106 PBMCs were fixed and permeabilized with Foxp3/Transcription Factor Staining
Buffer Set (eBioscience, Thermo Fisher Scientific, Waltham, MA, USA) and 5 µl of
purified anti FLIP antibody (D16A8; Cell Signaling Technologies, Danvers, MA,
USA) was added for 2 h at 4 °C. Signal was amplified with a secondary anti-rabbit
biotin-conjugated antibody (RG-16, 1:1500) Sigma-Aldrich (Saint Louis, MO, USA)
and with PerCP-Cy5.5-conjugated Streptavidin (eBioscience, Thermo Fisher
Scientific, Waltham, MA, USA) both for 30min at 4 °C.
Anti-PD-1 immunotherapy. The effect of anti-PD-1 immunotherapy was inves-
tigated in C57BL/6J mice after a s.c. challenge with 8 × 105 MCA205 cells. Tumor-
bearing mice with established tumor masses were treated using 4 iterative intra-
peritoneal administrations every 2 days of anti-PD-1 mAb (clone RMP1-14;
complete treatment 1 mg of Ab) or isotype Ab (clone 2A3; complete treatment
1 mg of Ab). After 3 days from the last treatment, we treated some mice by
adoptive cell transfer of 1 × 106 cells of: v-FLIP-expressing Ly6C+ cells or v-FLIP-
expressing Ly6G+ cells isolated from tg mice BM. In the control groups we
transferred 1 × 106 cells of: Ly6C+ cells or Ly6G+ cells isolated from WT mice BM.
Tumors were measured using digital calipers. Mice were euthanized when tumor
area reached 1650 mm3.
Adoptive cell therapy (ACT). The effects of ACT were investigated in C57BL/6J
mice after a s.c. challenge with 5 × 105 EG7-OVA cells. When the tumor area
reached ~300 mm3, mice received 1 × 106 antigen-activated OVA257–264 CTLs by
i.v. injection together with 1 × 106 Ly6C+ cells isolated from either Tg or WT mice.
Recombinant human IL-2 (30,000 IU) was administered twice a day i.p for 3
consecutive days from adoptive transfer9. Tumors were measured using digital
calipers. Mice were euthanized when tumor area reached 1,000 mm3.
Treg isolation. Thymic (t)Treg were sort-purified from peripheral blood mono-
nuclear cells by Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) isolated from
human apheresis products (Memorial Blood Center, St. Paul, MN) in a two-step
procedure whereby CD25+ cells (including tTreg) were positively selected using
GMP-grade mAb-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA) and
then sorted for naïve tTreg (CD4+25++127-45RA+). Purified cells were stimulated
with GMP-quality artificial antigen presenting cells (aAPC) and cultured for
14 days in high dose IL-2 (300 U/ml) as previously reported46. Expanded tTreg
were banked (frozen) on day 14. For the experiments described herein, tTreg were
thawed and re-stimulated with GMP-compliant anti-CD3/28 beads (Thermo-
Fisher Scientific, Waltham, MA) for 7–10 days. tTreg purity and in vitro sup-
pressive function were assessed at the end of the culture. The tTreg are simply
indicated as Treg in the text.
Xenogenic model of GvHD. NOG mice, were irradiated (120 rad) and intrave-
nously (i.v.) injected with 1 × 106 human peripheral blood mononuclear cells. After
21 days, when human CD3+ cells where ≥ 5% of total cells, mice were treated by
intravenous injection of c-FLIP-, luciferase-infected monocytes or tTreg. The
treatment was repeated 4 times on day 21, 28, 42, and 49. Mice were monitored for
immunological, clinical and histological scores.
Confocal microscopy. For immunofluorescence, cyto-spin slides (Shandon™ Single
Cytoslides™, Thermo Fisher Scientific, Waltham, MA, USA) were incubated with
the following primary antibodies: NF-kB p65 Mouse mAb (#6956, Cell Signaling,
Danvers, MA, USA), NF-kB2 p100/p52 Rabbit mAb (#3017, Cell Signaling, Dan-
vers, MA, USA), polyclonal rabbit anti-NF-κB p105/P50 picoband antibody
(PB9149, Boster Biological Technology, CA, USA), anti-NFkB p105/p50 antibody
(ab32360, Abcam), and monoclonal mouse anti-FLIP antibody (MAB8430, R&D
System). Alexa Fluor® 568 goat Anti-Mouse IgG (A11004, Invitrogen, Life Tech-
nologies, Carlsbad, CA, US), Alexa Fluor® 488 goat Anti-Mouse IgG (A11029,
Invitrogen, Life Technologies, Carlsbad, CA, US), Alexa Fluor® 647 goat Anti-
Rabbit IgG (A21244, Invitrogen, Life Technologies, Carlsbad, CA, US), Alexa
Fluor® 488 goat Anti-Rabbit IgG (A11008, Invitrogen, Life Technologies, Carlsbad,
CA, US), and Alexa Fluor® 546 goat Anti-Rabbit IgG (A11010, Invitrogen, Life
Technologies, Carlsbad, CA, US) were used as secondary antibodies. Nuclei were
stained with DAPI. Images were acquired with a Zeiss LSM 800 ZEN confocal
microscope. The slides were examined in double-blind and digital images of
representative areas were taken. The evaluation of NF-kB p65-p50-p52 nuclear
positivity was performed on confocal images of 10 THP1 cells and 26–38 Ly6C+ or
Ly6G+ cells per group with Adobe Photoshop by selecting the total nuclear Area
with the Lasso Tool, quantifying red or green staining with the Magic Wand Tool
and reporting the number of pixels indicated in the histogram window as per-
centage of the total nuclear area.
Histology and immunohistochemistry. Tissues were fixed in 10% neutral buf-
fered formalin and embedded into paraffin or fixed in 4% PFA and frozen in a
cryo-embedding medium (OCT, BioOptica, MI, Italy); after fixation, bones were
decalcified with 10% EDTA (pH 7.4) for 3 weeks and embedded into paraffin; 5 µm
thick sections were stained with Hematoxylin and Eosin (BioOptica, MI, Italy) for
histological examination. Pathological score was independently evaluated by two
pathologists in double-blind using the standard guideline previously published47.
For immunohistochemistry, mouse anti-human CD3 (LN10, Leica, Wetzlar, Ger-
many), rabbit anti-human CD14 (Sigma-Aldrich,Saint Louis, MO, USA) rat anti-
CD11b (550282, BD Pharmingen, San Jose, CA, USA) and rat anti-mouse Foxp3
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(14-5773-82, E-bioscience, Thermo Fisher Scientific, Waltham, MA, USA) anti-
bodies were used on cryostat sections while rabbit policlonal anti-CD3 (ab828,
Abcam, Cambridge, UK) and rat anti-mouse B220 (550286, BD Pharmingen, San
Jose, CA, USA) antibodies were used on paraffin sections. After incubation with the
appropriate secondary antibodies, immunostainings were developed with Vulcan
Fast Red (Biocare, MI, Italy) alkaline phosphatase or streptavidin peroxidase
(Thermo Scientific—Lab Vision Corp.)—DAB Chromogen (Dako, Santa Clara,
CA, USA) methods, respectively. After chromogen incubation, slides were coun-
terstained in Hematoxylin (BioOptica, MI, Italy) and images were acquired by
Leica DMRD optical microscope (Leica, Wetzlar, Germany).
Statistical analysis. All data are presented as mean ± standard error of the mean.
Statistical analysis was carried out using SigmaPlot (Systat Software). For statistical
comparison of two groups, non-parametric Mann-Whitney Wilcoxon test was
used. A value of P < 0.05 was considered significant.
Data availability
Microarray data are available at Gene Expression Omnibus under accession
GSE101587. The authors declare that all the other data supporting the findings of
this study are available within the article and its supplementary information files
and from the corresponding authors upon reasonable request.
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